There is evidence that low EZH2 levels correlate with more favorable chemotherapy results in cisplatin-based therapy in HNSCC (19), and that EZH2 overexpression reduces the cell response to cisplatin therapy in laryngeal SCC (28). Here, EZH2 is linked to head and neck squamous cell carcinoma.